NCT06443034View on ClinicalTrials.gov

Predictive Determinants of Nephrotic Syndrome Remission in Patients With At-risk Polymorphism of APOL1

Not yet recruitingOBSERVATIONAL

Enrollment

124

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2024

Conditions

Nephrotic SyndromeFocal Segmental GlomerulosclerosisAPOL1 Associated Kidney Disease

Trial Locations (1)

75020

Néphrologie & Dialyses department, Tenon Hospital, Paris

All Listed Sponsors

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT06443034 - Predictive Determinants of Nephrotic Syndrome Remission in Patients With At-risk Polymorphism of APOL1 | Biotech Hunter | Biotech Hunter